Tumor-induced modulation of dendritic cell function

被引:86
作者
Gottfried, Eva [2 ]
Kreutz, Marina [2 ]
Mackensen, Andreas [1 ,2 ]
机构
[1] Univ Erlangen Nurnberg, Dept Internal Med 5, D-91054 Erlangen, Germany
[2] Univ Regensburg, Dept Hematol Oncol, D-93042 Regensburg, Germany
关键词
antigen presenting cells; dendritic cells; cancer vaccination; tumor immune escape; tumor-specific T cells;
D O I
10.1016/j.cytogfr.2007.10.008
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Dendritic cells (DC) are specialized antigen presenting cells that acquire, process, and present tumor-associated antigens to T cells for the induction of antigen-specific tumor immune responses. DC have been shown to infiltrate many tumors but both, circulating and tumor-infiltrating DC from cancer patients, appear to be phenotypically and functionally defective. Several tumor-derived factors such as VEGF, IL6, IL-10, M-CSF, and STAT-3 have been shown to be responsible for systemic and local DC defects. Furthermore, tumor metabolites such as lactic acid may also critically contribute to DC dysfunction and tumor immune escape. The correction of abnormal DC function might be a requirement for successful vaccine approaches against cancer. (c) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:65 / 77
页数:13
相关论文
共 177 条
[1]   IL-6 as an intracrine growth factor for renal carcinoma cell lines [J].
Alberti, L ;
Thomachot, MC ;
Bachelot, T ;
Menetrier-Caux, C ;
Puisieux, I ;
Blay, JY .
INTERNATIONAL JOURNAL OF CANCER, 2004, 111 (05) :653-661
[2]   Migratory dendritic cells transfer antigen to a lymph node-resident dendritic cell population for efficient CTL priming [J].
Allan, Rhys S. ;
Waithman, Jason ;
Bedoui, Sammy ;
Jones, Claerwen M. ;
Villadangos, Jose A. ;
Zhan, Yifan ;
Lew, Andrew M. ;
Shortman, Ken ;
Heath, William R. ;
Carbone, Francis R. .
IMMUNITY, 2006, 25 (01) :153-162
[3]  
Allavena P, 1998, EUR J IMMUNOL, V28, P359, DOI 10.1002/(SICI)1521-4141(199801)28:01<359::AID-IMMU359>3.0.CO
[4]  
2-4
[5]  
Almand B, 2000, CLIN CANCER RES, V6, P1755
[6]  
AMBE K, 1989, CANCER, V63, P496, DOI 10.1002/1097-0142(19890201)63:3<496::AID-CNCR2820630318>3.0.CO
[7]  
2-K
[8]   Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development [J].
Aspord, Caroline ;
Pedroza-Gonzalez, Alexander ;
Gallegos, Mike ;
Tindle, Sasha ;
Burton, Elizabeth C. ;
Su, Dan ;
Marches, Florentina ;
Banchereau, Jacques ;
Palucka, A. Karolina .
JOURNAL OF EXPERIMENTAL MEDICINE, 2007, 204 (05) :1037-1047
[9]   Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients [J].
Bachelot, T ;
Ray-Coquard, I ;
Menetrier-Caux, C ;
Rastkha, M ;
Duc, A ;
Blay, JY .
BRITISH JOURNAL OF CANCER, 2003, 88 (11) :1721-1726
[10]   Increased levels of interleukin-10 in serum from patients with hepatocellular carcinoma correlate with profound numerical deficiencies and immature phenotype of circulating dendritic cell subsets [J].
Beckebaum, S ;
Zhang, X ;
Chen, X ;
Yu, ZY ;
Frilling, A ;
Dworacki, G ;
Grosse-Wilde, H ;
Broelsch, CE ;
Gerken, G ;
Cicinnati, VR .
CLINICAL CANCER RESEARCH, 2004, 10 (21) :7260-7269